Patents
Literature
7 results about "IDH1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Isocitrate dehydrogenase 1 (NADP+), soluble is an enzyme that in humans is encoded by the IDH1 gene on chromosome 2. Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which uses NAD⁺ as the electron acceptor and the other NADP⁺. Five isocitrate dehydrogenases have been reported: three NAD⁺-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP⁺-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. Each NADP⁺-dependent isozyme is a homodimer. The protein encoded by this gene is the NADP⁺-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes. It contains the PTS-1 peroxisomal targeting signal sequence. The presence of this enzyme in peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions, such as the conversion of 2,4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production. Alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Sep 2013]
Synthetic polyunsaturated fatty acid conjugated phospholipid yeast engineering bacteria, construction method and application thereof
ActiveCN121699770BIDH1Pyruvate synthesis
The present application relates to a kind of synthetic polyunsaturated fatty acid binding phospholipid yeast engineering bacteria and construction method and application, belong to microbial engineering technical field, the engineering bacteria is with Yarrowia lipolytica as bottom cell, knock out the Mhy1, Iro1, IDH1, CEX1 gene in its genome for generating mycelium, synthesis of triglyceride, citric acid metabolism, citric acid efflux;Phospholipid synthesis, pyruvate synthesis, polyunsaturated fatty acid synthesis and acyltransferase CDS1, OPI3, Mce2, LplA, △9Elo, △8Des, △5Des, △17Des, △5Elo, △15Des, LPCAT3 gene are sequentially connected together, as an expression module is integrated in the URA site of genome.The yeast engineering bacteria of the present application obtains polyunsaturated fatty acid binding phospholipid in one step efficiently, and phospholipid yield is 151.19 mg / g, and in binding fatty acid, EPA content is 13.2%.
Owner:YELLOW SEA FISHERIES RES INST CHINESE ACAD OF FISHERIES SCI
Pharmaceutical composition for use in the treatment of cancer
UndeterminedES3073326T3IDH1Mutant allele
Owner:LES LAB SERVIER SA
Compound for targeted degradation of mIDH1 protein and application thereof
PendingCN121930304AAddressing drug resistancerecovery functionOrganic active ingredientsDipeptide ingredientsIDH1Chemical compound
The invention relates to the technical field of medicines, in particular to a compound for targeted degradation of mIDH1 protein and application of the compound. According to the invention, a series of compounds with a 'PL-Linker-EL' ternary structure are creatively designed and synthesized, so that a fundamental treatment strategy breakthrough from traditional'protein function inhibition 'to direct'pathogenic protein removal' is realized. The compound can be combined with mutant IDH1 (mIDH1) protein and E3 ubiquitin ligase in a targeted manner at the same time, and then mIDH1 is induced to be subjected to ubiquitination modification and is thoroughly degraded through a proteasome way, so that the problem of drug resistance caused by mutation is expected to be overcome, and a new treatment choice is provided for patients who are invalid or relapse in the existing therapy.
Owner:TONGREN POLYTECHNIC COLLEGE
How to identify patients who are likely to benefit from telomerase inhibitor treatment
For example, to provide a method for identifying or selecting patients who are most likely to benefit from treatment with telomerase inhibitors such as imetelstat. [Solution] This disclosure provides a method for identifying or selecting patients who are most likely to benefit from treatment with telomerase inhibitors, such as imetelstat, by testing for high molecular weight risk (HMR) based on the absence of mutations in each of JAK2, CALR, and MPL, and / or the presence of a mutation in at least one of the following genes: ASXL1, EZH2, SRSF2, and IDH1 / 2. These patients may have myelofibrosis. This disclosure also provides a method for treating myelofibrosis, the method of which includes identifying such patients.
Owner:GERON CORP
Recombinant yarrowia lipolytica strain with high itaconic acid yield as well as construction method and application of recombinant yarrowia lipolytica strain
The invention discloses a recombinant yarrowia lipolytica strain with high yield of itaconic acid and a construction method and application thereof, and belongs to the field of strain cultivation, the recombinant yarrowia lipolytica strain is obtained by metabolism reconstruction of a wild type yarrowia lipolytica strain, a cis-aconitic acid decarboxylase gene cadA derived from Aspergillus terreus ATCC20542 is inserted into a genome, and a stable expression cassette is formed through a TEF1 promoter and a CYC1 terminator; a CIT1 gene front-end signal peptide is fused at the N end of the cadA to realize directional expression of mitochondria; iDH1, ACL1 and ADH1 genes are knocked out at the same time; cIT1 and ACO1 genes are overexpressed to enhance the flux of citric acid in the direction of cis-aconitic acid; and the noxE gene of Lactococcus lactis is introduced to regulate the balance of NADH (Nicotinamide Adenine Dinucleotide Hormone) in the cell. The strain is fermented for 72 hours under the conditions that glucose is used as a carbon source, the temperature is 30 DEG C and the pH value is 5.5-6.0, and the yield of itaconic acid can reach 12 g / L or above. According to the construction method, gene knockout and homologous recombination integration are realized by adopting CRISPR-Cas9, and a target strain is obtained after screening and verification. The method is used for preparing degradable polymers, plasticizers and medical intermediates. The method has the beneficial effects that the itaconic acid yield and metabolism efficiency are improved.
Owner:SHUANGHE (BEIJING) BIOTECHNOLOGY CO LTD
Application of IDH1 gene in porcine ovarian granular cells
The invention relates to an application of an IDH1 gene in porcine ovarian granular cells, in particular to an application in regulating proliferation and apoptosis of the porcine ovarian granular cells and / or steroid hormone synthesis and / or reproductive performance related gene expression. According to the invention, porcine ovarian granular cells are taken as objects, and the expression of the IDH1 gene is regulated to verify that the IDH1 gene is taken as a key target spot for regulating and controlling the functions of the porcine ovarian granular cells so as to influence steroid hormone synthesis and cell proliferation and apoptosis processes. A new molecular target is provided for improving the reproductive performance of the sow, more reliable technical support is provided for regulating and controlling the ovarian function, and a new thought and technical guidance are provided for mechanism research of reproductive diseases and preparation and development of related drugs.
Owner:HUNAN AGRI UNIV
Antibody of crotonylated isocitrate dehydrogenase 1 as well as preparation method and application thereof
The invention relates to an antibody of crotonylated isocitrate dehydrogenase 1 as well as a preparation method and application thereof, and particularly provides a polyclonal antibody, the polyclonal antibody is obtained by immunizing an animal through IDH1 crotonylated antigen epitope peptide, the specific site of the antigen epitope peptide is crotonylated, the high-titer antibody can be prepared, and the antibody can be used for preparing the isocitrate dehydrogenase 1. Crotonylation modification of IDH1 in a clinical specimen can be recognized with high specificity, and the compound can be used for immunoblotting and immunohistochemical research of cell / tissue specimens and diagnosis of IDH1 related diseases.
Owner:BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV